Altamira Therapeutics Ltd.
CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio—
52W High$0.4158
52W Low$0.3
Altamira Therapeutics Ltd. (CYTO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYTO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.01B) | ($0.00B) | ($0.03B) | ($0.02B) | ($0.01B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Net Cash from Operations | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | $0.00B | $0.01B | ($0.00B) | $0.00B |
| Net Cash from Financing | $0.01B | $0.01B | $0.01B | $0.01B | $0.02B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.01B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CHF · B
Explore more Altamira Therapeutics Ltd. data
About Altamira Therapeutics Ltd. (CYTO) Cash Flow Statement
Altamira Therapeutics Ltd. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2024 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
CYTO · 4 questionsAltamira Therapeutics Ltd. generated free cash flow of ($0.01B) for 2024, up 46.0% year-over-year.
CYTO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10